For families watching a loved one struggle to remember familiar names, conversations or everyday routines, the possibility of a new treatment that improves brain function without causing hallucinations offers a compelling reason for hope.
On October 13, 2026, American biotechnology company Jocasta Neuroscience and Canada-based Diamond Therapeutics announced a joint research program to investigate three experimental compounds inspired by psilocybin, the psychoactive substance found in certain mushrooms.
The collaboration aims to develop medicines that support cognitive performance while minimizing the perceptual disturbances associated with traditional psychedelics. The research will focus on cognitive impairment and neurodegenerative conditions, where treatment options remain limited.
However, the compounds are still experimental. Their potential benefits and non-hallucinogenic properties have not yet been demonstrated in human trials, making the announcement an early step toward developing possible future therapies rather than a medical breakthrough.
Three New Compounds Could Offer a Different Approach to Brain Health
The partnership brings together three new chemical entities discovered by Diamond Therapeutics and research funding from Jocasta Neuroscience. Each candidate is designed to interact with serotonin receptors in a pattern resembling psilocybin while avoiding signaling associated with hallucinations. The companies describe the substances as 5-HT2A receptor agonists, meaning they activate a receptor involved in psychedelic responses. The three molecules have not been publicly identified by name, and the announcement provides no comparative clinical results.
Diamond operates in Toronto and Birmingham, Alabama, while Jocasta is headquartered in Scottsdale, Arizona. Their immediate focus is cognitive impairment and neurodegeneration rather than recreational psychedelic use. Researchers hope medicinal chemistry can preserve beneficial biological activity without requiring patients to experience intense alterations in perception. Such an approach could be particularly relevant for older adults already struggling with memory loss or confusion. Nevertheless, the agreement establishes a research program, not proof that any candidate improves cognition or reverses dementia.
Scientists Will Test Cognitive Benefits and Potential Hallucinogenic Effects
The research plan calls for preclinical studies examining how each compound behaves in the body, affects behavior and influences cognitive performance. Scientists will assess pharmacokinetics, including how the substances are absorbed, distributed and cleared. Researchers also intend to investigate hallucinogenic-like effects, prioritizing candidates that demonstrate cognitive benefits without unwanted behavioral responses. These early experiments are important because animal behavior cannot fully reveal what a person might experience after taking an experimental medicine.
Existing research provides reasons for cautious optimism. A 2025 Nature Neuroscience study found that a separate psychedelic-inspired compound, tabernanthalog, promoted neural plasticity in rodents without certain effects associated with traditional psychedelics. However, a 2026 study in Translational Psychiatry found that a compound lacking the typical mouse head-twitch response still disrupted coordination, stress responses and cognition. Human research into psilocybin has also produced mixed cognitive outcomes. Consequently, researchers must establish whether these particular compounds are both effective and genuinely tolerable.
The Partnership Opens a New Research Pipeline, but Human Trials Remain Ahead
Jocasta will finance the research and provide Diamond with an upfront convertible debenture, exchangeable into preferred shares. If the studies prove sufficiently promising, Jocasta may obtain an exclusive license to develop, manufacture and commercialize the compounds. Diamond could then receive development and commercial milestone payments alongside royalties on net sales. Neither company disclosed the financial amounts, and the agreement does not guarantee that a license will eventually be exercised.
The partnership is separate from Jocasta’s lead program, JN-0413, an experimental therapy based on the alpha-klotho protein that is expected to enter first-in-human trials in early 2027. No human-trial timetable was announced for the three psychedelic-inspired candidates. The need for better treatments is substantial: approximately 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia in 2026. Before becoming available to patients, these compounds must demonstrate acceptable safety and meaningful effectiveness through rigorous clinical research. For families affected by cognitive decline, measurable improvements in everyday functioning would ultimately matter far more than promising laboratory results.
